About kiniksa pharmaceuticals international plc - KNSA
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
KNSA At a Glance
Kiniksa Pharmaceuticals International Plc
105 Piccadilly
London, Greater London W1J 7NJ
| Phone | 44-781-431-9100 | Revenue | 677.56M | |
| Industry | Pharmaceuticals: Major | Net Income | 59.01M | |
| Sector | Health Technology | 2025 Sales Growth | 60.09% | |
| Fiscal Year-end | 12 / 2026 | Employees | 366 | |
| View SEC Filings |
KNSA Valuation
| P/E Current | 63.352 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 55.213 |
| Price to Sales Ratio | 4.808 |
| Price to Book Ratio | 5.545 |
| Price to Cash Flow Ratio | 23.61 |
| Enterprise Value to EBITDA | 36.221 |
| Enterprise Value to Sales | 4.211 |
| Total Debt to Enterprise Value | 0.003 |
KNSA Efficiency
| Revenue/Employee | 1,851,267.76 |
| Income Per Employee | 161,215.847 |
| Receivables Turnover | 43.45 |
| Total Asset Turnover | 1.008 |
KNSA Liquidity
| Current Ratio | 3.788 |
| Quick Ratio | 3.393 |
| Cash Ratio | 2.975 |
KNSA Profitability
| Gross Margin | 54.63 |
| Operating Margin | 11.397 |
| Pretax Margin | 13.116 |
| Net Margin | 8.708 |
| Return on Assets | 8.779 |
| Return on Equity | 11.73 |
| Return on Total Capital | 10.224 |
| Return on Invested Capital | 11.565 |
KNSA Capital Structure
| Total Debt to Total Equity | 1.673 |
| Total Debt to Total Capital | 1.646 |
| Total Debt to Total Assets | 1.244 |
| Long-Term Debt to Equity | 1.147 |
| Long-Term Debt to Total Capital | 1.128 |